Abstract:Objective To investigate the efficacy and safety of the cetuximab combined with chemotherapy for patients with metastasis from colorectal cancer whose K-Ras status were wild type and explore the factors that may affect the efficacy and prognosis. Methods Retrospectively collected the clinical data of 90 patients with metastasis from colorectal cancer whose K-Ras status were wild type. Cetuximab 400mg/m2 was intravenously given at first dose and maintenance at 250mg/m2 every week or 500mg/m2 every two weeks. Combined chemotherapy regimen included, irinotecan-based chemotherapy(FOLFIRI or XELIRI or irinotecan monotherapy), oxaliplatin-based chemotherapy( FOLFOX or XELOX) ,other regimens, such as 5-FU/leucovorin or capecitabine monotherapy. The ef-ficacy and safety of each line of chemotherapy was summarized and assessed, and the relationship between clinicopathology features, treatment characteristics and efficacy, explore the factors associated with prognosis were analyzed retrospectively. Results The median duration treatment of cetuximab was 16 weeks( 6-44 weeks) . And in all patients the objective response rate( ORR) was 45?6%,and the disease control rate( DCR) was 87?8%. The DCR in first line treatment was 51?6% better than in second line, whose was 40?0%, and the DCR in third line was 18?2%. The age, location of primary tumor, treatment time of cetuximab might affect the efficacy fo cetux- imab plus chemotherapy. In the 90 patients, recurrent metastases were occurred in 82 cases( 91?1%) and death in 60 cases( 66?7%) . The median PFS( mPFS) was 7?8 months and median OS( mOS) was 22?5 months. In the first line treatment of cetuximab plus chemo-therapy, mPFS was 9?1 months and mOS was 27?6 months. In second line treatment mPFS was 7?7 months and mOS was 14?5 month. in third line mPFS was 2?9 months and mOS was 6?7 months. Univariate survival analysis showed that the location of primary tumor, early tumor response and treatment time of cetuximab were related to PFS and OS of the patients, and the metastasis scope was related to the OS of patients. Using the Cox multivariate hazards model to analysis the clinicopathological factors, which showed that the loca-tion of primary tumor and early tumor response were the independent risk factors affecting the PFS of patients, the metastasis scope was the independent risk factor affecting the OS of patients. The most common adverse reaction related to cetuximab is acne-like rash, the side effects associated with chemotherapy mainly were diarrhea, nausea, vomiting, bone marrow suppression. After symptomatic treat-ment, patients can tolerate. Conclusion Cetuximab combined chemotherapy in each line treatment of patients with metastases from colorectal cancer can get great efficacy, and the adverse reactions can be tolerated. The location of primary tumor might be the predic-tors of the efficacy, and it is also associated with the prognosis of the patients. As ETS Shows that early tumor response could be one of the outcome indicators of mCRC.

Right- and Left-Sided Colorectal Cancers Respond Differently to Cetuximab

A Study of Gene Variation in All-RAS Wild-Type Metastatic Colorectal Cancer and Its Correlation with Cetuximab.

Patients with RAS Wild-Type Right-Sided Unresectable Liver-Confined Mcrc Also Benefit from Cetuximab Plus Chemotherapy in First-Line Treatment

Cetuximab Plus Mfolfox-6 As First-Line Therapy for Unresectable Liver Metastasis from Colorectal Cancer: an Open, Non-Randomized, Multicenter Phase Ii Clinical Trial

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17

The Optimal First-Line Treatment for Patients with Left-Sided RAS Wild-Type Metastatic Colorectal Cancer: Double-drug Regimen or Triple-Drug Regimen Therapy

Different Treatment Strategies and Molecular Features Between Right-Sided and Left-Sided Colon Cancers

Tumor Response and Secondary Resectability of Colorectal Liver Metastases Following Cetuximab with Chemotherapy: A Randomized, Controlled Study

Phase II APEC Trial: the Impact of Primary Tumor Side on Outcomes of First‐line Cetuximab Plus FOLFOX or FOLFIRI in Patients with RAS Wild‐type Metastatic Colorectal Cancer

Impact of Primary Tumor Side on Clinical Outcomes of First-Line Cetuximab Plus FOLFOX-4 in RAS Wild-Type Metastatic Colorectal Cancer.

Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.

Efficacy of Cetuximab-Based Chemotherapy in Metastatic Colorectal Cancer According to RAS and BRAF Mutation Subgroups: A Meta-Analysis

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells During Treatment of Colorectal Cancer

Randomized Controlled Trial of Cetuximab Plus Chemotherapy for Patients with KRAS Wild-Type Unresectable Colorectal Liver-Limited Metastases.

Transverse colon primary tumor location as a biomarker in metastatic colorectal cancer: A pooled analysis of CCTG/AGITG CO.17 and CO.20 randomized clinical trials

The impact of primary tumor location on efficacy of cetuximab in metastatic colorectal cancer patients with different Kras status: a systematic review and meta-analysis.

Molecular characterization of metastatic colorectal cancer (mCRC) in patients (pts) treated with cetuximab and pembrolizumab.

Efficacy analysis of cetuximab plus chemotherapy for K-Ras wild-type colorectal cancer with metastases

[Efficacy of cetuximab combined with chemotherapy for patients with advanced colorectal cancer and unclear K-ras status].

Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis

Efficacy of Cetuximab Combined with Chemotherapy on Advanced Colorectal Cancer: a Report of 53 Cases